Assessing the Impact of Cancer Prevention on Self-Reported Health and Well-Being

  • Stephen Joel CoonsEmail author
  • Mira J. Patel


Cancer can lead to decreases in both the length and quality of life, which is a compelling reason to prevent it. However, to more fully demonstrate the wisdom of cancer prevention, it is important to quantify, to the extent possible, the short- and long-term impact of cancer prevention-related activities on self-reported health and well-being. Although unlikely to lead to immediate gains in quality of life, prevention can avoid or delay reductions in quality of life over time. Based on early empirical research, it appears that the predominantly transient negative consequences of participating in routine cancer prevention activities are readily offset by the positive long-term outcomes; however, more research is needed. Even though the ultimate success of cancer prevention strategies is judged by the number of cancer cases prevented, the assessment of more proximal self-reported outcomes can help enhance our understanding of the willingness of individuals to participate in them.


Patient-reported outcomes PRO measures Humanistic outcomes Cancer screening Quality-adjusted life years Health-related quality of life Self-report Cancer prevention 


  1. American Cancer Society (2016) Can ovarian cancer be prevented. American Cancer Society, Atlanta. Scholar
  2. Aaronson NK, Ahmedzai S et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRefGoogle Scholar
  3. Badia X, Herdman M (2001) The importance of health-related quality of life data in determining the value of drug therapy. Clin Ther 23(1):168–175CrossRefGoogle Scholar
  4. Bennetts A, Irwig L et al (1995) PEAPS-Q: a questionnaire to measure the psychosocial effects of having an abnormal Pap smear. J Clin Epidemiol 48(10):1235–1243CrossRefGoogle Scholar
  5. Bowling A (1997) Measuring health: a review of quality of life measurement scales. Open University Press, PhiladelphiaGoogle Scholar
  6. Bowling A (2001) Measuring disease: a review of disease-specific quality of life measurement scales. Open University Press, PhiladelphiaGoogle Scholar
  7. Brandberg Y, Sandelin K et al (2008) Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 26(24):3943–3949CrossRefGoogle Scholar
  8. Brazier J, Roberts J et al (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21(2):271–292CrossRefGoogle Scholar
  9. Brettschneider C, Lühmann D, Raspe H (2011) Informative value of patient reported outcomes (PRO) in health technology assessment (HTA). GMS Health Technol Assess 7:Doc01. Scholar
  10. Broderson J, Thorsen H et al (2007) Validation of a condition-specific measure for women having an abnormal screening mammography. Value Health 10(4):294–304CrossRefGoogle Scholar
  11. Bruner DW, Movsas B et al (2004) Outcomes research in cancer clinical trial cooperative groups: the RTOG model. Qual Life Res 13(6):1025–1041CrossRefGoogle Scholar
  12. Campbell CMP, Menezes LJ, Paskett ED, Giuliano AR (2012) Prevention of invasive cervical cancer in the United States: past, present, and future. Cancer Epidemiol Biomark Prev 21(9):1402–1408CrossRefGoogle Scholar
  13. Cappelleri JC, Zou KH et al (2014) Patient-reported outcomes: measurement, implementation and interpretation. CRC Press, Boca RatonGoogle Scholar
  14. Cella DF, Tulsky DS et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579CrossRefGoogle Scholar
  15. Centers for Disease Control and Prevention (2018) Possible side-effects from vaccines.
  16. Cullen J, Schwartz MD et al (2004) Short-term impact of cancer prevention and screening activities on quality of life. J Clin Oncol 22(5):943–952CrossRefGoogle Scholar
  17. Donaldson MS (2004) Taking stock of health-related quality-of-life measurement in oncology practice in the United States. J Natl Cancer Inst Monogr 33:155–167CrossRefGoogle Scholar
  18. Einstein MH, Baron M et al (2009) Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin 5(10):705–719CrossRefGoogle Scholar
  19. European Medicines Agency (2005) Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products.
  20. Fang CY, Cherry C, Devarajan K, Li T, Malick J, Daly MB (2009) A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol Oncol 112(3):594–600CrossRefGoogle Scholar
  21. Ferrans CE (2005) Definitions and conceptual models of quality of life. In: Lipscomb J, Gotay CC, Snyder C (eds) Outcomes assessment in cancer: measures, methods, and applications. Cambridge University Press, Cambridge, pp 14–30Google Scholar
  22. Frost MH, Hoskin TL et al (2011) Contralateral prophylactic mastectomy: long term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. Ann Surg Oncol 18(11):3110–3116CrossRefGoogle Scholar
  23. Gelber RD, Goldhirsch A et al (1993) Evaluation of effectiveness: Q-TWiST. The International Breast Cancer Study Group. Cancer Treat Rev 19(Suppl A):73–84CrossRefGoogle Scholar
  24. Gold MR, Stevenson D, Fryback DG (2002) HALYs and QALYs and DALYs, oh my: similarities and differences in summary measures of population health. Annu Rev Public Health 23:115–134CrossRefGoogle Scholar
  25. Grant M, Ferrell B et al (2004) Revision and psychometric testing of the City of Hope Quality of Life—Ostomy Questionnaire. Qual Life Res 13:1445–1458CrossRefGoogle Scholar
  26. Guyatt GH, Feeny DH et al (1993) Measuring health-related quality of life. Ann Intern Med 118(8):622–629CrossRefGoogle Scholar
  27. Hoffman KE, McCarthy EP, Recklitis CJ, Ng AK (2009) Psychological distress in long-term survivors of adult-onset cancer: results from a national survey. Arch Intern Med 169(14):1274–1281CrossRefGoogle Scholar
  28. Karnofsky D, Burchenal J (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod C (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New YorkGoogle Scholar
  29. Kozma CM, Reeder CE et al (1993) Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther 15(6):1121–1132; discussion 1120PubMedGoogle Scholar
  30. Lipscomb J, Donaldson MS et al (2004) Cancer outcomes research and the arenas of application. J Natl Cancer Inst Monogr 33:1–7CrossRefGoogle Scholar
  31. Lipscomb J, Snyder CF (2002) The Outcomes of Cancer Outcomes Research: focusing on the National Cancer Institute’s quality-of-care initiative. Med Care 40(6 Suppl):III3–III10PubMedGoogle Scholar
  32. Lipscomb J, Gotay CC, Snyder C (eds) (2005) Outcomes assessment in cancer: measures, methods, and applications. Cambridge University Press, CambridgeGoogle Scholar
  33. Litwin MS, Hays RD et al (1998) The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 36(7):1002–1012CrossRefGoogle Scholar
  34. Mandelblatt JS, Selby JV (2005) Short-term outcomes of chemoprevention, genetic susceptibility testing, and screening interventions: what are they? How are they measured? When should they be measured? In: Lipscomb J, Gotay CC, Snyder C (eds) Outcomes assessment in cancer: measures, methods, and applications. Cambridge University Press, Cambridge, pp 216–240Google Scholar
  35. McDowell I (2006) Measuring health: a guide to rating scales and questionnaires, 3rd edn. Oxford University Press, OxfordCrossRefGoogle Scholar
  36. Mukherjee S (2010) The emperor of all maladies: a biography of cancer. Scribner, New YorkGoogle Scholar
  37. Muñoz N, Manalastas R Jr et al (2009) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 373(9679):1949–1957CrossRefGoogle Scholar
  38. National Cancer Institute (2017) Cancer trends progress report.
  39. Padamsee TJ, Wills CE, Yee LD, Paskett ED (2017) Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Res 19(1):34CrossRefGoogle Scholar
  40. Patrick DL, Deyo RA (1989) Generic and disease-specific measures in assessing health status and quality of life. Med Care 27(3 Suppl):S217–S232CrossRefGoogle Scholar
  41. Phillips KM, Jim HS et al (2011) Cognitive functioning after cancer treatment. Cancer 118(7):1925–1932CrossRefGoogle Scholar
  42. Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ (2009) Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg 124(2):345–353CrossRefGoogle Scholar
  43. Ramsey SD, Fedorenko CR et al (2011) Cancer diagnosis as a risk factor for personal bankruptcy. J Clin Oncol 29(15 suppl):6007CrossRefGoogle Scholar
  44. Razdan SN, Patel V, Jewell S, McCarthy CM (2016) Quality of life among patients after bilateral prophylactic mastectomy: a systematic review of patient-reported outcomes. Qual Life Res 25(6):1409–1421CrossRefGoogle Scholar
  45. Reeve BB, Potosky AL et al (2009) Impact of cancer on health-related quality of life of older Americans. J Natl Cancer Inst 101(12):860–868CrossRefGoogle Scholar
  46. Revicki DA, Osoba D et al (2000) Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 9:887–900CrossRefGoogle Scholar
  47. Siegel R, DeSantis C et al (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62(4):220–241CrossRefGoogle Scholar
  48. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30CrossRefGoogle Scholar
  49. Short PF, Moran JR, Punekar R (2011) Medical expenditures of adult cancer survivors aged <65 years in the United States. Cancer 117(12):2791–2800CrossRefGoogle Scholar
  50. Short PF, Vasey JJ, Tunceli K (2005) Employment pathways in a large cohort of adult cancer survivors. Cancer 103(6):1292–1301CrossRefGoogle Scholar
  51. Sirgy MJ, Michalos AC et al (2006) The quality-of-life (QOL) research movement: past, present, and future. Soc Indic Res 76:343–466CrossRefGoogle Scholar
  52. Staquet M, Aaronson N et al (1992) Health-related quality of life research. Qual Life Res 1:3CrossRefGoogle Scholar
  53. Stillo M, Carrillo Santisteve P, Lopalco PL (2015) Safety of human papillomavirus vaccines: a review. Expert Opin Drug Saf 14(5):697–712CrossRefGoogle Scholar
  54. Streiner DL, Norman GR, Cairney J (2015) Health measurement scales: a practical guide to their development and use, 5th edn. Oxford University Press, OxfordCrossRefGoogle Scholar
  55. Tengs TO, Wallace A (2000) One thousand health-related quality-of-life estimates. Med Care 38(6):583–637CrossRefGoogle Scholar
  56. Ubel P (2001) Pricing life: why it’s time for health care rationing. MIT Press, CambridgeGoogle Scholar
  57. US Food and Drug Administration (2009) Guidance for industry—patient-reported outcome measures: use in medical product development to support labeling claims.…/Guidances/UCM193282.pdf
  58. Ware JE Jr (2000) SF-36 health survey update. Spine 25(24):3130–3139CrossRefGoogle Scholar
  59. Ware J, Kosinski M, Keller S (1994) SF-36 physical and mental health summary scales: a user’s manual. The Health Institute, BostonGoogle Scholar
  60. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483CrossRefGoogle Scholar
  61. Weaver KE, Forsythe LP et al (2012) Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomark Prev 21(11):2108–2117CrossRefGoogle Scholar
  62. Willke RJ, Burke LB, Erickson P (2004) Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 25:535–552CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Patient-Reported Outcome ConsortiumCritical Path InstituteTucsonUSA
  2. 2.Department of Pharmacy Practice and ScienceUniversity of Arizona College of PharmacyTucsonUSA

Personalised recommendations